Literature DB >> 21918968

The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria.

Funso Abogunrin1, Hugh F O'Kane, Mark W Ruddock, Michael Stevenson, Cherith N Reid, Joe M O'Sullivan, Neil H Anderson, Declan O'Rourke, Brian Duggan, John V Lamont, Ruth E Boyd, Peter Hamilton, Thiagarajan Nambirajan, Kate E Williamson.   

Abstract

BACKGROUND: We appraised 23 biomarkers previously associated with urothelial cancer in a case-control study. Our aim was to determine whether single biomarkers and/or multivariate algorithms significantly improved on the predictive power of an algorithm based on demographics for prediction of urothelial cancer in patients presenting with hematuria.
METHODS: Twenty-two biomarkers in urine and carcinoembryonic antigen (CEA) in serum were evaluated using enzyme-linked immunosorbent assays (ELISAs) and biochip array technology in 2 patient cohorts: 80 patients with urothelial cancer, and 77 controls with confounding pathologies. We used Forward Wald binary logistic regression analyses to create algorithms based on demographic variables designated prior predicted probability (PPP) and multivariate algorithms, which included PPP as a single variable. Areas under the curve (AUC) were determined after receiver-operator characteristic (ROC) analysis for single biomarkers and algorithms.
RESULTS: After univariate analysis, 9 biomarkers were differentially expressed (t test; P < .05). CEA AUC 0.74; bladder tumor antigen (BTA) AUC 0.74; and nuclear matrix protein (NMP22) 0.79. PPP included age and smoking years; AUC 0.76. An algorithm including PPP, NMP22, and epidermal growth factor (EGF) significantly improved AUC to 0.90 when compared with PPP. The algorithm including PPP, BTA, CEA, and thrombomodulin (TM) increased AUC to 0.86. Sensitivities = 91%, 91%; and specificities = 80%, 71%, respectively, for the algorithms.
CONCLUSIONS: Addition of biomarkers representing diverse carcinogenic pathways can significantly impact on the ROC statistic based on demographics. Benign prostate hyperplasia was a significant confounding pathology and identification of nonmuscle invasive urothelial cancer remains a challenge.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21918968     DOI: 10.1002/cncr.26544

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Biomarker profiling of plasma samples utilizing RANDOX biochip array technology.

Authors:  Jennifer Saluk; Debra Hoppensteadt; Danyel Syed; Jeffrey Liles; Schuharazad Abro; Amanda Walborn; Vinod Bansal; Jawed Fareed
Journal:  Int Angiol       Date:  2017-06-09       Impact factor: 2.789

Review 2.  Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Authors:  Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks
Journal:  Nat Rev Urol       Date:  2013-02-26       Impact factor: 14.432

Review 3.  Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.

Authors:  V Urquidi; C J Rosser; S Goodison
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 4.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

5.  MULTIPLEX URINARY TESTS FOR BLADDER CANCER DIAGNOSIS.

Authors:  Virginia Urquidi; Charles J Rosser; Steve Goodison
Journal:  Eur Med J Urol       Date:  2013

Review 6.  Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests.

Authors:  Steve Goodison; Charles J Rosser; Virginia Urquidi
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

7.  Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat.

Authors:  Cherith N Reid; Michael Stevenson; Funso Abogunrin; Mark W Ruddock; Frank Emmert-Streib; John V Lamont; Kate E Williamson
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

8.  Collectives of diagnostic biomarkers identify high-risk subpopulations of hematuria patients: exploiting heterogeneity in large-scale biomarker data.

Authors:  Frank Emmert-Streib; Funso Abogunrin; Ricardo de Matos Simoes; Brian Duggan; Mark W Ruddock; Cherith N Reid; Owen Roddy; Lisa White; Hugh F O'Kane; Declan O'Rourke; Neil H Anderson; Thiagarajan Nambirajan; Kate E Williamson
Journal:  BMC Med       Date:  2013-01-17       Impact factor: 8.775

9.  A pilot study combining a GC-sensor device with a statistical model for the identification of bladder cancer from urine headspace.

Authors:  Tanzeela Khalid; Paul White; Ben De Lacy Costello; Raj Persad; Richard Ewen; Emmanuel Johnson; Chris S Probert; Norman Ratcliffe
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

10.  The use of molecular analyses in voided urine for the assessment of patients with hematuria.

Authors:  Willemien Beukers; Raju Kandimalla; Diandra van Houwelingen; Hrvoje Kovacic; Jie-Fen D Chin; Hester F Lingsma; Lars Dyrskjot; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.